Outlook Therapeutics Stalled: FDA Rejects Key AMD Treatment
Event summary
- Outlook Therapeutics' resubmission of its Biologics License Application (BLA) for ONS-5010/LYTENAVA™ (bevacizumab-vikg) for wet AMD has been rejected with a Complete Response Letter (CRL) by the FDA.
- The FDA cited a need for confirmatory efficacy data, despite the NORSE TWO trial demonstrating efficacy, but did not specify the type of data required.
- LYTENAVA™ is already approved in the EU and UK, where it launched in Germany and the UK in June 2025.
- The NORSE EIGHT trial, a non-inferiority study comparing ONS-5010 to ranibizumab, is now under scrutiny as a potential source of the required confirmatory data.
The big picture
This CRL underscores the challenges in bringing biosimilars to market, particularly in areas with established standard-of-care treatments like wet AMD. While LYTENAVA™ has secured European approvals, the U.S. market represents a significant revenue opportunity, and this setback significantly impacts Outlook Therapeutics' growth trajectory. The company's ability to navigate the FDA's evolving expectations will be crucial for its long-term viability.
What we're watching
- Regulatory Headwinds
- The FDA's lack of clarity regarding acceptable confirmatory data creates significant uncertainty, potentially requiring a lengthy and costly new development pathway for ONS-5010.
- Clinical Trial Design
- The success of any future trials will hinge on the FDA’s evolving requirements, and the design of those trials will be critical to avoid another CRL.
- Financial Stability
- Given the ongoing development costs and potential delays, Outlook Therapeutics’ financial resources will be tested, and partnerships or funding rounds may become necessary.
Related topics